The treatment of multidrug-resistant tuberculosis (TB) requires the use, for long periods, of drugs liable to cause significant side effects.
Introduction
A belief that is still held by infectious diseases physicians and microbiologists is that the incidence of non-tuberculous mycobacteria (NTM) is increasing in countries with low tuberculosis (TB) endemicity, whereas it is close to zero in developing countries characterized by a high TB burden. It is much more likely that the increased isolation of NTM in the developed world is a consequence of the advanced diagnostic technologies that can be afforded, and the apparent absence of NTM in developing countries is imputable to the very limited use of culture for diagnosis in the large majority of such settings [1] . The legitimacy of the latter hypothesis is confirmed by a number of studies reporting the isolation of NTM in Africa once sensitive cultural methods had been adopted [2] [3] [4] [5] .
We report here the case of a African patient who was repeatedly, and unsuccessfully, treated for pulmonary TB, and who rapidly improved once the non-tuberculous aetiology was acknowledged and suitable therapy was introduced.
Case report
A 62-year-old Somali man was admitted to the Infectious Diseases Unit because of a long-standing history of low-grade fever, weakness, weight loss, dyspnoea and productive cough. He had joined his son and his daughter in Italy 2 months previously. His medical history included malaria, approximately 40 years before, and pulmonary TB. The diagnosis of TB had been made in Somalia, when the patient was 58 years of age; he carried no medical records, but reported that he had been given chemotherapy. Although he was unable to provide details about the drugs he had been taking, he reported at least five interruptions to the therapy because of the war in progress in his country.
Computed tomography showed extensive bilateral lesions, consistent with the diagnosis of pulmonary TB. This diagnosis, apparently supported by sputum smears strongly positive for acid-fast bacilli and by the first culture data, led to standard treatment with isoniazid, rifampicin, pyrazinamide and ethambutol. After 4 weeks of such treatment, which was well tolerated, the results of the susceptibility testing (Table 1) led to discontinuation of rifampicin, isoniazid and pyrazinamide (the susceptibility test result for the last of these was not yet available) and the addition of amikacin, ethionamide, moxifloxacin and linezolid to ethambutol [6] .
The general condition of the patient rapidly improved and, again, the treatment was well tolerated. Three weeks later, the sputum smears became negative and the patient was discharged. Following the final recognition of the strain as a non-tuberculous mycobacterium, clarithromycin (shown, in the meantime, to be effective in vitro) was substituted for linezolid because of the high risk of toxicity associated with prolonged treatment with the latter drug. Two months later, amikacin was discontinued. The patient is now receiving clinical follow-up, and his biochemical and microbiological parameters are being checked regularly; continuation of the treatment is planned for at least 12 months.
Radiology
The chest computed tomography scan showed marked retraction of the right lung, with deviation of the mediastinum and consolidation of the right pulmonary lobes. These showed lesions characteristic of tuberculous infection, with multiple cavitations in a breadcrumb-like pattern, and a large cavity, communicating with the bronchial tree, clearly visible in the upper lobe ( Fig. 1 ). In the upper left lobe, parenchymal infiltrates with aerial bronchogram were present, and opacities in a 'tree in bud' pattern [7] affected the lingula (Fig. 2) . The identification of the strain (FI-09026) as belonging to the MTBC was apparently confirmed by the reverse hybridization line probe assay GenoType Mycobacterium CM (Hain Lifescience, Nehren, Germany) [9] targeting the 23S rDNA. The use of a further reverse hybridization test, GenoType MTBC (Hain Lifescience) [10] , suitable for differentiating the species included in the MTBC, however, produced further confusion. Again, a positive result was obtained with the MTBC-specific line probe, but none of the nine gyrB stretches harbouring polymorphisms characterizing single MTBC species could be amplified.
Genetic investigation of mutations responsible for rifampicin and isoniazid resistance, performed using GenoType MTBDRplus (Hain Lifescience) [11] , to verify the suspicion of multidrug-resistant TB, was not able to detect any, either mutant or wild type, of the specific targets (rpoB, inhA and katG). The test confirmed, however, the presence of a sequence of 23S rRNA specific for the MTBC.
Antimicrobial susceptibility testing was at first performed according to the proportion method (validated for M. tuberculosis strains only) in MGIT medium, using a wide panel of first-line and second-line drugs [12] . It revealed a pattern (Table 1) suggestive of multidrug-resistant TB.
When the MICs were determined using the microdilution method recommended by the CLSI for NTM [13] , most of the second-line drugs, among them linezolid and amikacin, were shown to be effective ( Table 1) .
HPLC of cell wall mycolic acids, undertaken to try to resolve these identification uncertainties, revealed a pattern characterized by a single, late cluster of peaks, which differed from those obtained with M. tuberculosis [14] in the relative heights of several peaks (Fig. 3) .
Despite the multiple indications that the strain belonged to the MTBC, several findings did not seem to support such a hypothesis. A genetic sequencing approach was therefore attempted to try to resolve the problem. Double-strand sequencing was implemented using BigDye Terminator chemistry and an AB3730 DNA sequencer (Applied Biosystems, Foster City, CA, USA) on four genetic species markers of primary importance for the taxonomic and phylogenetic analysis of mycobacteria. In addition to the 16S rDNA gene, universally considered to be the first choice [15] , the hypervariable region of the gene encoding for the 65-kDa heat shock protein (hsp65) [16] and the internal transcribed spacer (ITS) interposed between the 16S and the 23S rDNAs [17] were sequenced. A recently proposed fragment of the rpoB gene [18] was also investigated.
All of the sequences above turned out to be unique and more closely related to the recently described species Mycobacterium riyadhense [19] . In the almost complete sequence of the 16S rDNA of the current isolate, FI-09026 (GenBank accession number FJ786255), the similarity to the latter species was 99%, with nine mismatches in 1438 bp. In the hypervariable region of hsp65 [20] (accession number FJ786253), there were 13 mismatches (in 423 bp; similarity 96%). In the ITS (accession number FJ786255), the presence of 13 mismatches in 278 bp was responsible for a similarity of 95%. In the 744-bp stretch of rpoB (FJ786254), M. riyadhense did not appear, at first, to be the closest species; however, once we realized that, for the latter species, this genetic region was not yet present in GenBank and we had determined such a sequence in the type strain (accession number FJ786256), M. riyadhense again turned out to present the closest similarity (95%, with 37 mismatches). In the same regions, the similarities with M. tuberculosis were clearly lower: 98% in the 16S rDNA, 86% in hsp65, 88% in the ITS, and 91% in rpoB.
Surprisingly, in the first part of the 23S rDNA (accession number FJ786255), which is known to include the target on which the GenoType identification probes rely, the similarity of FI-09066 to M. tuberculosis was also low (<97%).
The phylogenetic analysis conducted using the neighbourjoining algorithm (MEGA 4 software) [21] on the 1730-bp sequence, including the 16S rDNA and ITS, demonstrated the relatedness of FI-09026 and M. riyadhense (with the two strains belonging, however, to clearly distinct branches) and the sharp divergence from M. tuberculosis (Fig. 4) .
Discussion
This is the second report of a mycobacterial strain, phenotypically mimicking M. tuberculosis but nevertheless clearly distinct from it, being responsible for severe disease that is indistinguishable from TB. The first case concerned a 19-year-old male with painful swelling of the left side of his face due to a tumour in the maxillary sinus extending into the nasal septum and the left orbit. Because of the isolation of a mycobacterium from lavage of maxillary sinuses, the patient was treated with a 9-month anti-TB regimen, which produced a clear improvement. A thorough characterization of the strain revealed it to be a non-tuberculous mycobacterium, and led to the description of the new species M. riyadhense [19] .
Major features shared by FI-09026 and M. riyadhense include the bacillary morphology, the colony appearance, the misidentification as M. tuberculosis by GenoType CM, and the unquestionable pathogenicity. They differ, however, in antimicrobial susceptibility, both in vitro and in vivo: the infection due to M. riyadhense was successfully treated with standard anti-TB therapy that was ineffective against FI-09026.
The similarity of FI-09026 to M. tuberculosis is striking. Microscopically, FI-09026 is characterized by lengthened and curved bacillary morphology, similarly to M. tuberculosis. Likewise, colonies grown on solid media are rough and non-pigmented, similar to colonies of M. tuberculosis, and require comparable incubation periods to become visible to the naked eye. The arrangement of bacilli in liquid MGIT medium is characterized by the cord morphology that is considered to be a distinctive feature of M. tuberculosis [22] . The pattern of results of the main biochemical tests used for species identifications is very close (data not shown), with only the niacin result being discrepant: consistently positive in M. tuberculosis (but not in other species of the MTBC) and negative in FI-09026. The HPLC profile of cell wall mycolic acids did not allow unquestionable differentiation. The antimicrobial susceptibility is clearly different from that of M. tuberculosis but, paradoxically, the resistance of FI-09026 to the first-line anti-TB drugs, instead of suggesting a possible non-tuberculous mycobacterium, brought to mind a multidrug-resistant M. tuberculosis strain. The hybridization pattern obtained using the popular molecular identification system GenoType CM does not distinguish FI-09026 from the MTBC.
As a consequence of the above-mentioned features, the probability of misdiagnosis of multidrug-resistant TB is very high. This is true for low-income countries, in which the diagnosis of TB relies on smear microscopy only [23] , but is equally true for a high proportion of laboratories in the developed world, including practically all those that base the identification of mycobacteria on methods other than genetic sequencing.
At present, we can only speculate about the real distribution of strains with the features of FI-09026. They may, indeed, not be very rare, and the major objective of this article is to alert the medical community to the possibility that some isolates considered to be multidrug-resistant M. tuberculosis may not actually be so.
Although we are unwilling to describe a new species until additional strains are detected, we propose, for the strain characterized here, the name 'Mycobacterium simulans' (simulans meaning 'imitative'). The strain has been deposed in the German Collection of Microorganisms and Cell Cultures with the accession number DSM45395.
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